The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 39 results
Sort by date: Descending
Encores: Not included
SLEEP (Annual Meeting of the Associated Professional Sleep Societies)
June 7th – 11th 2025
Sleep-wake disorders
PRESENTATION
Investigational Orexin-2 Receptor Agonists for Narcolepsy Types 1 and 2, Idiopathic Hypersomnia, and Beyond
AUTHOR(S)

Presented by Marcus Yountz

View presentation
Sleep-wake disorders
American Society of Clinical Psychopharmacology
May 27th – 30th 2025
Bipolar Disorder
Schizophrenia
POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
International Society for Pharmacoeconomics and Outcomes Research, Inc
May 13th – 16th 2025
Sleep-wake disorders
POSTER
The Economic Burden of Narcolepsy in the United States: Matched Analysis of National Health and Wellness Survey Data
AUTHOR(S)

Michael J. Doane1, Kiran P. Maski2, M. Janelle Cambron-Mellott3, Shakiba Eslamimehr3, Adam Jauregui3, Wilbur P. Williams, III1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Academy of Managed Care Pharmacy
March 31st – April 3rd 2025
Schizophrenia
POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

View poster
Listen to Audio Abstract
0:00 0:00
Schizophrenia
Schizophrenia International Research Society
March 29th – April 2nd 2025
Bipolar Disorder
Schizophrenia
POSTER
Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 David McDonnell, MD,3 Christoph U. Correll, MD4-7

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
US Psych Congress Annual
October 29th – November 2nd 2024
Bipolar Disorder
POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

View poster
Bipolar Disorder